Stephanie Rose Harrison

Stephanie Rose Harrison

Auto-generated profile, based on publicly available information

Stephanie Rose Harrison

NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust , Leeds

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
HMHelena Marzo-Ortega
Helena Marzo-Ortega
SHStephanie Rose Harrison
Stephanie Rose Harrison
György NagyGyörgy Nagy
György Nagy
PMPedro M Machado
Pedro M Machado
DMDennis G McGonagle
Dennis G McGonagle
SSStefan Siebert
Stefan Siebert

25 November 2023 in Best Practice & Research Clinical Rheumatology
Verified
Journal Article
Closed access
SKSamantha O. Kohn
Samantha O. Kohn
AAAbeera Azam
Abeera Azam
LHLauren E. Hamilton
Lauren E. Hamilton
SHStephanie R. Harrison
Stephanie R. Harrison
EGElizabeth R. Graef
Elizabeth R. Graef
JLJean Liew
Jean Liew

9 December 2023 in Rheumatology Advances in Practice
Verified
Journal Article
Open access
PDF file
JWJake Weddell
Jake Weddell
NDNaw Ra Aung Din
Naw Ra Aung Din
SHStephanie R Harrison
Stephanie R Harrison
XMXabier Michelena
Xabier Michelena
DMDennis McGonagle
Dennis McGonagle
HMHelena Marzo-Ortega
Helena Marzo-Ortega
Objective: The aim was to assess the use and drug survival of IL-17Ai in a real-world cohort of axial SpA (axSpA) and PsA patients. Methods: Patients ever commenced on an IL-17Ai (secukinumab or ixekizumab) for axSpA or PsA at the Leeds Specialist Spondyloarthritis Service were identified. Demographics, IL-17Ai treatment length and reason for cessation were collected. Drug survival data were plotted as a Kaplan–Meier curve, with log rank test of median survival compared between axSpA and PsA. Cox regression analysis was performed to investigate the relationship between diagnosis and length of drug survival. Results: In total, 228 patients (91 axSpA and 137 PsA) were exposed to IL-17Ai. Drug survival for all patients at 12 months was 69% (95% Confidence Interval (CI) 63, 75%) and at 24 months 60% (95% CI 54, 67%). In axSpA and PsA, drug survival at 12 months was 63% (CI 54, 74%) and 73% (CI 66, 81%), respectively, and at 24 months it was 53% (CI 44, 65%) and 65% (CI 57, 75%), respectively. Median survival did not differ significantly between both diseases (log rank test 0.65). There was no association between diagnosis and survival (hazard ratio 0.92, 95% CI 0.63, 1.33), including when adjusting for age, previous biologic DMARD usage and sex (hazard ratio 0.89, 95% CI 0.61, 1.13). Conclusion: This is the first study, to our knowledge, to analyse and compare real-world IL-17Ai drug survival in patients with axSpA and PsA from a single centre. We demonstrate that there is no difference in IL-17Ai survival rates and no relationship between diagnosis and drug survival. These results contribute to the body of real-world evidence confirming the role of IL-17Ai in the management of axSpA and PsA.

26 August 2021 in Expert Review of Clinical Immunology
Verified
Journal Article
Open access
SHStephanie R Harrison
Stephanie R Harrison
HMHelena Marzo-Ortega
Helena Marzo-Ortega
Axial spondyloarthritis (axSpA) is an inflammatory arthritis which affects primarily the entheses of the spine and sacroiliac joints with peripheral joint synovitis and extra-articular manifestatio...

4 January 2021 in Rheumatology
Verified
Journal Article
Closed access
SHStephanie R Harrison
Stephanie R Harrison
ABAgata N Burska
Agata N Burska
PEPaul Emery
Paul Emery
HMHelena Marzo-Ortega
Helena Marzo-Ortega
Frédérique PonchelFrédérique Ponchel
Frédérique Ponchel
Objective: Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints. TNF inhibitor (TNFi) drugs are recommended for patients not responding to NSAIDs; however, there is a significant need for biomarkers of response. IFN-regulated genes (IRGs) and other cytokines/chemokines are linked to autoimmune diseases and have been associated with treatment response. Our objective was to explore whether IRGs and cytokines/chemokines can be associated with response to TNFiagents in AS. Methods: Peripheral blood mononuclear cells were obtained from 26 AS patients who were to receive a TNFi (I, n = 15) or placebo (P, n = 11) at week 0 and week 22. Response (R)/non-response (NR) was defined as reduction in ASDAS ≥ 1.2 points or reduction in sacroiliac/vertebral MRI lesions. The expression of 96 genes was quantified using TaqMan assays. Finally, ELISA was used to measure IL-6 in serum samples from another 38 AS patients. Results: Analysis of gene expression in 26 baseline samples segregated patients into four groups defined by a signature of 15 genes (mainly IRGs). ASDAS response was associated with one group independently of treatment received. We then analysed response to the TNFi (n = 15) and identified a 12-gene signature associated with MRI response. A third IRG signature was also associated with a reduction in IRGs expression post-TNFi samples (n = 10 pairs). Finally, decreased circulating IL-6 was associated with BASDAI-R. Conclusion: This pilot study suggests an association between IRG expression and response to TNFi in AS. These findings require validation in a larger cohort in order to construct predictive algorithms for patient stratification.

9 February 2021 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SHStephanie R Harrison
Stephanie R Harrison
JKJ. R. L. Klassen
J. R. L. Klassen
CBCharlie Bridgewood
Charlie Bridgewood
ASAndrew Scarsbrook
Andrew Scarsbrook
HMHelena Marzo‐Ortega
Helena Marzo‐Ortega
DMDennis McGonagle
Dennis McGonagle
Background Radiological and pathological studies in severe COVID‐19 pneumonia (SARS‐CoV‐2) have demonstrated extensive pulmonary immunovascular thrombosis and infarction. This study investigated whether these focal changes may present with chest pain mimicking PE in ambulant patients. Methods CTPAs from outpatients presenting with chest pain to Leeds Teaching Hospital NHS Trust 1st March to 31st May 2020 (n=146) and 2019 (n=85) were compared. Regions of focal ground glass opacity (GGO), consolidation and/or atelectasis (parenchymal changes) were determined, all scans were scored using British Society for Thoracic Imaging (BSTI) criteria for COVID‐19, and the 2020 cohort were offered SARS‐CoV‐2 antibody testing. Results Baseline demographic and clinical data were similar between groups with absence of fever, normal lymphocytes and marginally elevated CRP and D‐Dimer values. Evidence of COVID‐19 or parenchymal changes were observed in 32.9%(48/146) of cases in 2020 compared to 16.5%(14/85) in 2019(p=0.007). 11/146(7.5%) patients met BSTI criteria for COVID‐19 in 2020 compared with 0/14 in 2019(p=0.008). 3/39 patients tested had detectable COVID‐19 antibodies (2 with parenchymal changes and 1 with normal parenchyma) however 0/6 patients whose CTPA met BSTI criteria “likely/suspicious for COVID‐19” and attended antibody testing were SARS‐CoV‐2 antibody positive Conclusions 32.8% ambulatory patients with suspected PE in 2020 had parenchymal changes with 7.5% diagnosed as COVID‐19 infection by imaging criteria, despite absence of other COVID‐19 symptoms. These findings suggest that localised COVID‐19 pneumonitis with immunothrombosis occurs distal to the bronchiolar arteriolar circulation, causing pleural irritation and chest pain without viraemia, accounting for the lack of fever and systemic symptoms.